A comprehensive review on novel targeted therapy methods and nanotechnology-based gene delivery systems in melanoma

  1. Rahimi, Azadeh
  2. Esmaeili, Yasaman
  3. Dana, Nasim
  4. Dabiri, Arezou
  5. Rahimmanesh, Ilnaz
  6. Jandaghian, Setareh
  7. Vaseghi, Golnaz
  8. Shariati, Laleh
  9. Zarrabi, Ali
  10. Haghjooy Javanmard, Shaghayegh
  11. Cordani, Marco
Revista:
European Journal of Pharmaceutical Sciences

ISSN: 0928-0987

Ano de publicación: 2023

Volume: 187

Páxinas: 106476

Tipo: Artigo

DOI: 10.1016/J.EJPS.2023.106476 GOOGLE SCHOLAR lock_openAcceso aberto editor

Outras publicacións en: European Journal of Pharmaceutical Sciences

Obxectivos de Desenvolvemento Sustentable

Resumo

Melanoma, a malignant form of skin cancer, has been swiftly increasing in recent years. Although there have been significant advancements in clinical treatment underlying a well-understanding of melanoma-susceptible genes and the molecular basis of melanoma pathogenesis, the permanency of response to therapy is frequently constrained by the emergence of acquired resistance and systemic toxicity. Conventional therapies, including surgical resection, chemotherapy, radiotherapy, and immunotherapy, have already been used to treat melanoma and are dependent on the cancer stage. Nevertheless, ineffective side effects and the heterogeneity of tumors pose major obstacles to the therapeutic treatment of malignant melanoma through such strategies. In light of this, advanced therapies including nucleic acid therapies (ncRNA, aptamers), suicide gene therapies, and gene therapy using tumor suppressor genes, have lately gained immense attention in the field of cancer treatment. Furthermore, nanomedicine and targeted therapy based on gene editing tools have been applied to the treatment of melanoma as potential cancer treatment approaches nowadays. Indeed, nanovectors enable delivery of the therapeutic agents into the tumor sites by passive or active targeting, improving therapeutic efficiency and minimizing adverse effects. Accordingly, in this review, we summarized the recent findings related to novel targeted therapy methods as well as nanotechnology-based gene systems in melanoma. We also discussed current issues along with potential directions for future research, paving the way for the next-generation of melanoma treatments.

€ Ver financiamento

Información de financiamento

Financiadores

Referencias bibliográficas

  • Abal, (2003), Curr Cancer Drug Targets, 3, pp. 193, 10.2174/1568009033481967
  • Abate-Daga, (2010), Biochim Biophys Acta, 1803, pp. 1175, 10.1016/j.bbamcr.2010.06.009
  • Alshamsan, (2010), Mol. Pharmaceutics, 7, pp. 1643, 10.1021/mp100067u
  • Amin, (2019), pp. 151
  • Amreddy, (2018), Adv Cancer Res, 137, pp. 115, 10.1016/bs.acr.2017.11.003
  • Aoude, (2015), J Natl Cancer Inst, 107, 10.1093/jnci/dju408
  • Aoude, (2015), Pigment Cell Melanoma Res, 28, pp. 148, 10.1111/pcmr.12333
  • Argus, (2017), Comput Biol Med, 84, pp. 226, 10.1016/j.compbiomed.2017.04.001
  • Armstrong, (2015), Journal of Investigative Dermatology, 135, pp. 1629, 10.1038/jid.2015.45
  • Atkins, (2021), Clin Cancer Res, 27, pp. 2678, 10.1158/1078-0432.CCR-20-4092
  • Avril, (2004), J Clin Oncol, 22, pp. 1118, 10.1200/JCO.2004.04.165
  • Bai, (2020), Mol Ther Oncolytics, 17, pp. 9, 10.1016/j.omto.2020.03.002
  • Bajpai, (2020), Theranostics, 10, pp. 7841, 10.7150/thno.42291
  • Baker, (2020), F1000Res, 9, pp. 281, 10.12688/f1000research.23185.1
  • Balch, (2001), J Clin Oncol, 19, pp. 3635, 10.1200/JCO.2001.19.16.3635
  • Balch, (2009), J Clin Oncol, 27, pp. 6199, 10.1200/JCO.2009.23.4799
  • Ballantyne, (2013), Drugs, 73, pp. 1367, 10.1007/s40265-013-0095-2
  • Barrett, (2015), Int J Cancer, 136, pp. 1351, 10.1002/ijc.29099
  • Baskar, (2014), Front Mol Biosci, 1, pp. 24, 10.3389/fmolb.2014.00024
  • Baylis, (2017), Curr Gene Ther, 17, pp. 309
  • Beane, (2015), Mol Ther, 23, pp. 1380, 10.1038/mt.2015.71
  • Begg, (2005), J Natl Cancer Inst, 97, pp. 1507, 10.1093/jnci/dji312
  • Behan, (2019), Nature, 568, pp. 511, 10.1038/s41586-019-1103-9
  • Bertolotto, (2011), Nature, 480, pp. 94, 10.1038/nature10539
  • Bhan, (2017), Cancer Res, 77, pp. 3965, 10.1158/0008-5472.CAN-16-2634
  • Bhatia, (2009), Oncology (Williston Park), 23, pp. 488
  • Bian, (2018), Biomed Pharmacother, 108, pp. 165, 10.1016/j.biopha.2018.08.152
  • Bishop, (2002), J Natl Cancer Inst, 94, pp. 894, 10.1093/jnci/94.12.894
  • Blakney, (2019), ACS Nano, 13, pp. 5920, 10.1021/acsnano.9b01774
  • Blakney, (2020), ACS Nano, 14, pp. 5711, 10.1021/acsnano.0c00326
  • Blázquez, (2006), The FASEB journal, 20, pp. 2633, 10.1096/fj.06-6638fje
  • Bolhassani, (2014), IntechOpen, pp. 1
  • Bonnekoh, (1996), Journal of investigative dermatology, 106, pp. 1163, 10.1111/1523-1747.ep12347786
  • Borroni, (2017), Acta Biomater, 59, pp. 303, 10.1016/j.actbio.2017.07.007
  • Borzillo, (2021), Cancers (Basel), 13, 10.3390/cancers13225859
  • Bottillo, (2018), Clin Genet, 93, pp. 934, 10.1111/cge.13129
  • Buchbinder, (2016), Am J Clin Oncol, 39, pp. 98, 10.1097/COC.0000000000000239
  • Buck, (2019), ACS Nano, 13, pp. 3754, 10.1021/acsnano.8b07858
  • Calzada, (2017), Bioorg Med Chem, 25, pp. 1163, 10.1016/j.bmc.2016.12.026
  • Canton, (2017), Immunotherapy, 9, pp. 1309, 10.2217/imt-2017-0096
  • Cardoso, (2018), European Journal of Lipid Science and Technology, 120, 10.1002/ejlt.201700212
  • Carlos-Reyes, (2021), Front Oncol, 11, 10.3389/fonc.2021.718636
  • Cengelli, (2010), Nanomedicine, 5, pp. 1075, 10.2217/nnm.10.79
  • Cerezo-Wallis, (2020), Nature medicine, 26, pp. 1865, 10.1038/s41591-020-1073-3
  • Chatterjee, (2018), Semin Cancer Biol, 51, pp. 149, 10.1016/j.semcancer.2017.08.004
  • Chen, (2017), ACS Appl. Mater. Interfaces, 9, pp. 4457, 10.1021/acsami.6b14184
  • Chen, (2018), Adv Healthc Mater, 7, 10.1002/adhm.201700978
  • Chen, (2022), Chem Eng J, 431
  • Chen, (2019), Nat Commun, 10, pp. 877, 10.1038/s41467-019-08691-3
  • Chen, (2018), Adv Drug Del Rev, 127, pp. 85, 10.1016/j.addr.2017.12.014
  • Chen, (2020), Life Sci, 243, 10.1016/j.lfs.2020.117323
  • Chong, (2013), J Control Release, 166, pp. 211, 10.1016/j.jconrel.2012.12.030
  • Chowdhury, (2020), J Control Release, 326, pp. 75, 10.1016/j.jconrel.2020.06.008
  • Chudnovsky, (2005), J Clin Invest, 115, pp. 813, 10.1172/JCI24808
  • Cirielli, (1995), Int J cancer, 63, pp. 673, 10.1002/ijc.2910630512
  • Cocconi, (1992), N Engl J Med, 327, pp. 516, 10.1056/NEJM199208203270803
  • Cole, (1995), Cancer Res, 55, pp. 748
  • Cornu, (2017), Nat Med, 23, pp. 415, 10.1038/nm.4313
  • Coulie, (2014), Nat Rev Cancer, 14, pp. 135, 10.1038/nrc3670
  • Craciun, (2019), Molecules, 24, 10.3390/molecules24081460
  • Craciun, (2019), Molecules, 24, pp. 1460, 10.3390/molecules24081460
  • Dany, (2016), Hum Vaccin Immunother, 12, pp. 2501, 10.1080/21645515.2016.1190889
  • Davis, (2019), Cancer Biol Ther, 20, pp. 1366, 10.1080/15384047.2019.1640032
  • Di Cristofano, (2000), Cell, 100, pp. 387, 10.1016/S0092-8674(00)80674-1
  • Diotti, (2011), Nucleus, 2, pp. 119, 10.4161/nucl.2.2.15135
  • Doench, (2016), Nat Biotechnol, 34, pp. 184, 10.1038/nbt.3437
  • Domingues, (2018), Immunotargets Ther, 7, pp. 35, 10.2147/ITT.S134842
  • Dudley, (2008), J Clin Oncol, 26, pp. 5233, 10.1200/JCO.2008.16.5449
  • Dummer, (2000), Cancer gene therapy, 7, pp. 1069, 10.1038/sj.cgt.7700214
  • Duncan, (2022), J Control Release, 341, pp. 44, 10.1016/j.jconrel.2021.11.013
  • Düzgüneş, (2019), Suicide Gene Therapy, pp. 1
  • Eggermont, (2004), Eur J Cancer, 40, pp. 1825, 10.1016/j.ejca.2004.04.030
  • Ercolano, (2019), Front Pharmacol, 10, pp. 1456, 10.3389/fphar.2019.01456
  • Escoffre, (2013), Curr Gene Ther, 13, pp. 2, 10.2174/156652313804806606
  • Eshhar, (1993), Proc Natl Acad Sci U S A, 90, pp. 720, 10.1073/pnas.90.2.720
  • Fang, (2003), Cancer Biol Ther, 2, pp. S115
  • Fargnoli, (2010), Eur J Cancer, 46, pp. 1413, 10.1016/j.ejca.2010.01.027
  • Fesnak, (2016), Nat Rev Cancer, 16, pp. 566, 10.1038/nrc.2016.97
  • Filon, (2015), Regul Toxicol Pharmacol, 72, pp. 310, 10.1016/j.yrtph.2015.05.005
  • Fink, (2006), Gene Ther, 13, pp. 1048, 10.1038/sj.gt.3302761
  • Fisher, (1976), The Lancet, 2, pp. 337, 10.1016/S0140-6736(76)92592-7
  • Flaherty, (2012), N Engl J Med, 367, pp. 1694, 10.1056/NEJMoa1210093
  • Florell, (2005), J Clin Oncol, 23, pp. 7168, 10.1200/JCO.2005.11.999
  • Foote, (2008), ANZ J Surg, 78, pp. 273, 10.1111/j.1445-2197.2008.04436.x
  • Franklin, (2017), Eur J Surg Oncol, 43, pp. 604, 10.1016/j.ejso.2016.07.145
  • Freire, (2023), Colloids and Surfaces A: Physicochemical and Engineering Aspects, 658, 10.1016/j.colsurfa.2022.130676
  • Friedman, (2021), Adv Ther, 38, pp. 3506, 10.1007/s12325-021-01783-x
  • Gane, (1997), The Lancet, 350, pp. 1729, 10.1016/S0140-6736(97)05535-9
  • Garbe, (2009), Clin Dermatol, 27, pp. 3, 10.1016/j.clindermatol.2008.09.001
  • Garbe, (2008), Dtsch Arztebl Int, 105, pp. 845
  • García-Garrido, (2021), Pharmaceutics, 13, pp. 2067, 10.3390/pharmaceutics13122067
  • Gautron, (2021), EMBO Mol Med, 13, pp. e13466, 10.15252/emmm.202013466
  • Gholami, (2017), Trends in Pharmaceutical Sciences, 3, pp. 221
  • Gholami, (2020), J. Nanomaterials, 2020, 10.1155/2020/1852946
  • Goedert, (2016), Oncotarget, 7, pp. 36711, 10.18632/oncotarget.9164
  • Goldstein, (2006), Cancer Res, 66, pp. 9818, 10.1158/0008-5472.CAN-06-0494
  • Goldstein, (2007), J Med Genet, 44, pp. 99, 10.1136/jmg.2006.043802
  • Gonçalves, (2017), RSC Adv, 7, pp. 14496, 10.1039/C6RA28633J
  • Greaney, (2020), Cancer Immunol Res, 8, pp. 246, 10.1158/2326-6066.CIR-19-0359
  • Green, (2008), Acc Chem Res, 41, pp. 749, 10.1021/ar7002336
  • Green, (2007), Adv Mat, 19, pp. 2836, 10.1002/adma.200700371
  • Greig, (2016), Drugs, 76, pp. 147, 10.1007/s40265-015-0522-7
  • Guan, (2021), Front Bioeng Biotechnol, 9, 10.3389/fbioe.2021.661214
  • Guzman, (2006), British Journal of Cancer, 95, pp. 197, 10.1038/sj.bjc.6603236
  • Haase-Kohn, (2022), Cells, 11, 10.3390/cells11040749
  • Hainzl, (2017), Mol Ther, 25, pp. 2573, 10.1016/j.ymthe.2017.07.005
  • Hao, (2022), Histol Histopathol, 37, pp. 373
  • Harris, (2021), Biotech Prog, 37, pp. e3066, 10.1002/btpr.3066
  • Hartman, (2015), Cell Mol Life Sci, 72, pp. 1249, 10.1007/s00018-014-1791-0
  • Hatakeyama, (2011), Adv Drug Deliv Rev, 63, pp. 152, 10.1016/j.addr.2010.09.001
  • Heller, (2010), Curr Gene Ther, 10, pp. 312, 10.2174/156652310791823489
  • Heo, (2016), Oncol Rep, 36, pp. 1779, 10.3892/or.2016.5032
  • Hinz, (2022), British Journal of Cancer, 127, pp. 1, 10.1038/s41416-022-01727-4
  • Hodi, (2013), J Clin Oncol, 31, pp. 3182, 10.1200/JCO.2012.47.7836
  • Hooshmand, (2021), Materials, 14, pp. 3337, 10.3390/ma14123337
  • Horn, (2013), Science, 339, pp. 959, 10.1126/science.1230062
  • Hu, (2006), Clin Cancer Res, 12, pp. 6737, 10.1158/1078-0432.CCR-06-0759
  • Hughes, (2005), Hum Gene Ther, 16, pp. 457, 10.1089/hum.2005.16.457
  • Hunder, (2008), N Engl J Med, 358, pp. 2698, 10.1056/NEJMoa0800251
  • Ihle, (2015), Mol Oncol, 9, pp. 1421, 10.1016/j.molonc.2015.03.013
  • Ilyas, (2015), J Immunol, 195, pp. 5117, 10.4049/jimmunol.1501657
  • Jayaraman, (2012), Angew Chem Int Ed Engl, 51, pp. 8529, 10.1002/anie.201203263
  • Jenkins, (2021), J Invest Dermatol, 141, pp. 23, 10.1016/j.jid.2020.03.943
  • Jinturkar, (2011), pp. 45
  • Johnstone, (2014), Anticancer Res, 34, pp. 471
  • Jones, (2012), Nat Rev Genet, 13, pp. 484, 10.1038/nrg3230
  • Ju, (2018), Am J Cancer Res, 8, pp. 1788
  • Klatzmann, (1998), Human gene therapy, 9, pp. 2585
  • Kleinstiver, (2016), Nature, 529, pp. 490, 10.1038/nature16526
  • Kryza, (2016), PLoS One, 11, 10.1371/journal.pone.0149387
  • Kucerova, (2008), J Gene Med, 10, pp. 1071, 10.1002/jgm.1239
  • Kulkarni, (2019), Acc Chem Res, 52, pp. 2435, 10.1021/acs.accounts.9b00368
  • Kulkarni, (2021), Nat Nanotechnol, 16, pp. 630, 10.1038/s41565-021-00898-0
  • Kumar, (2019), RSC Adv, 9, pp. 23894, 10.1039/C9RA03608C
  • Kuryk, (2020), Cancers (Basel), 12, pp. 3057, 10.3390/cancers12103057
  • Labala, (2017), Int J Pharm, 525, pp. 407, 10.1016/j.ijpharm.2017.03.087
  • Latorre, (2021), Nanomedicine: Nanotechnology, Biology and Medicine, 35
  • Legha, (1990), Cancer, 65, pp. 2478, 10.1002/1097-0142(19900601)65:11<2478::AID-CNCR2820651114>3.0.CO;2-S
  • Lens, (2003), Cancer, 98, pp. 1355, 10.1002/cncr.11644
  • Lesueur, (2016), Mol Ther Nucleic Acids, 5, pp. e291, 10.1038/mtna.2016.4
  • Leung, (2012), Cancer J, 18, pp. 176, 10.1097/PPO.0b013e31824bc981
  • Levine, (1997), Cell, 88, pp. 323, 10.1016/S0092-8674(00)81871-1
  • Li, (2019), Mol Ther Nucleic Acids, 18, pp. 727, 10.1016/j.omtn.2019.10.005
  • Li, (2016), Oncol Res, 23, pp. 205, 10.3727/096504016X14549667334007
  • Li, (2014), Biomaterials, 35, pp. 3840, 10.1016/j.biomaterials.2014.01.019
  • Li, (2016), Biomaterials, 111, pp. 124, 10.1016/j.biomaterials.2016.09.019
  • Li, (2020), Genomics Proteomics Bioinformatics, 18, pp. 26, 10.1016/j.gpb.2020.02.002
  • Lio, (2019), Nanoscale, 11, pp. 17041, 10.1039/C9NR06303J
  • Liu, (2017), Biomaterials, 134, pp. 166, 10.1016/j.biomaterials.2017.04.043
  • Liu, (2014), Mol Cell Pharmacol, 6, pp. 228
  • Livingstone, (2014), Chin Clin Oncol, 3, pp. 29
  • Lopes-Nunes, (2020), Eur J Pharm Biopharm, 154, pp. 228, 10.1016/j.ejpb.2020.07.018
  • Lostalé-Seijo, (2018), Nat Rev Chem, 2, pp. 258, 10.1038/s41570-018-0039-1
  • Loureiro, (2020), Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 10.1016/j.bbcan.2020.188438
  • Luan, (2018), Mol Ther Nucleic Acids, 12, pp. 220, 10.1016/j.omtn.2018.05.005
  • Lugowska, (2018), Contemp Oncol (Pozn), 22, pp. 61
  • Luo, (2018), RSC Adv, 8, pp. 6053, 10.1039/C7RA13607B
  • Lux, (2018), Adv Exp Med Biol, 1087, pp. 215, 10.1007/978-981-13-1426-1_17
  • Malloggi, (2015), Polym Chem, 6, pp. 6325, 10.1039/C5PY00915D
  • Manguso, (2017), Nature, 547, pp. 413, 10.1038/nature23270
  • McNeish, (2001), Cancer Gene Ther, 8, pp. 308, 10.1038/sj.cgt.7700305
  • Menezes, (2014), Anticancer Genes, pp. 127, 10.1007/978-1-4471-6458-6_6
  • Menezes, (2018), Advances in cancer research, 138, pp. 213, 10.1016/bs.acr.2018.02.007
  • Milan-Rois, (2021), Cancers (Basel) 13
  • Mishra, (2018), J Cancer Res Clin Oncol, 144, pp. 2283, 10.1007/s00432-018-2726-1
  • Mohammadpour, (2019), J Cell Physiol, 234, pp. 3307, 10.1002/jcp.27286
  • Morgan, (2006), Science, 314, pp. 126, 10.1126/science.1129003
  • Morgan, (2003), J Immunol, 171, pp. 3287, 10.4049/jimmunol.171.6.3287
  • Moses, (2019), Mol Ther Nucleic Acids, 14, pp. 287, 10.1016/j.omtn.2018.12.003
  • Muller, (2018), G3 (Bethesda), 8, pp. 1475, 10.1534/g3.117.300394
  • Nagler, (2020), Pigment Cell Melanoma Res, 33, pp. 334, 10.1111/pcmr.12825
  • Nakamura, (2017), Mol Med, 23, pp. 295, 10.2119/molmed.2017.00099
  • Nakamura, (2019), J Oncol, 2019, 10.1155/2019/7387601
  • Nakanishi, (2013), Semin Immunopathol, 35, pp. 123, 10.1007/s00281-012-0342-8
  • Niezgoda, (2015), Biomed Res Int, 2015, 10.1155/2015/851387
  • Niu, (2017), ACS Appl Mater Interfaces, 9, pp. 9388, 10.1021/acsami.6b16378
  • O'Leary, (2016), Nat Rev Clin Oncol, 13, pp. 417, 10.1038/nrclinonc.2016.26
  • Ochyl, (2018), Biomaterials, 182, pp. 157, 10.1016/j.biomaterials.2018.08.016
  • Ojima, (2014), Lab Invest, 94, pp. 422, 10.1038/labinvest.2014.5
  • Oliveira Pinho, (2019), Nanomaterials (Basel), 9, 10.3390/nano9101455
  • Olmeda, (2017), Nature, 546, pp. 676, 10.1038/nature22977
  • Onitilo, (2020), Surg Clin North Am, 100, pp. 161, 10.1016/j.suc.2019.09.009
  • Pan, (2018), Sci Rep, 8, pp. 1
  • Pastorino, (2020), Cancers (Basel), 12, 10.3390/cancers12041007
  • Pereira, (2018), Oncotarget, 9, pp. 26934, 10.18632/oncotarget.25260
  • Pereira, (2017), Sci Rep, 7, pp. 1, 10.1038/srep44236
  • Pertwee, (2006), Int J Obesity, 30, pp. S13, 10.1038/sj.ijo.0803272
  • Pradhan, (2019), Oncotarget, 10, pp. 5103, 10.18632/oncotarget.27150
  • Prosen, (2013), Biomed Res Int, 2013, 10.1155/2013/209452
  • Puig-Saus, (2019), Immunooncol Technol, 1, pp. 19, 10.1016/j.iotech.2019.06.001
  • Puntervoll, (2013), J Med Genet, 50, pp. 264, 10.1136/jmedgenet-2012-101455
  • Quereux, (2011), Expert Opin Pharmacother, 12, pp. 2891, 10.1517/14656566.2011.633513
  • Quirico, (2020), Int J Biol Sci, 16, pp. 1238, 10.7150/ijbs.39768
  • Quirt, (2007), Oncologist, 12, pp. 1114, 10.1634/theoncologist.12-9-1114
  • Ran, (2013), Cell, 154, pp. 1380, 10.1016/j.cell.2013.08.021
  • Rancan, (2012), ACS Nano, 6, pp. 6829, 10.1021/nn301622h
  • Rao, (2015), Small, 11, pp. 239, 10.1002/smll.201400775
  • Rapoport, (2015), Nat Med, 21, pp. 914, 10.1038/nm.3910
  • Read, (2016), J Med Genet, 53, pp. 1, 10.1136/jmedgenet-2015-103150
  • Robbins, (2011), J Clin Oncol, 29, pp. 917, 10.1200/JCO.2010.32.2537
  • Robert, (2015), N Engl J Med, 372, pp. 320, 10.1056/NEJMoa1412082
  • Robert, (2017), J Clinic Oncology, 35, pp. 9504, 10.1200/JCO.2017.35.15_suppl.9504
  • Robert, (2014), Lancet, 384, pp. 1109, 10.1016/S0140-6736(14)60958-2
  • Robert, (2015), N Engl J Med, 372, pp. 2521, 10.1056/NEJMoa1503093
  • Robles-Espinoza, (2014), Nat Genet, 46, pp. 478, 10.1038/ng.2947
  • Rosenberg, (2008), Nat Rev Cancer, 8, pp. 299, 10.1038/nrc2355
  • Rossi, (2019), Dermatol Pract Concept, 9, pp. 10, 10.5826/dpc.0901a03
  • Ruan, (2018), Int J Pharm, 553, pp. 298, 10.1016/j.ijpharm.2018.10.043
  • Rutkowski, (2010), Cancers (Basel), 2, pp. 824, 10.3390/cancers2020824
  • Sarkar, (2008), Cancer gene therapy, 15, pp. 293, 10.1038/cgt.2008.14
  • Sauane, (2008), Proc Natl Acad Sci, 105, pp. 9763, 10.1073/pnas.0804089105
  • Schumacher, (2015), Science, 348, pp. 69, 10.1126/science.aaa4971
  • Schwartz, (2021), J Control Release, 339, pp. 531, 10.1016/j.jconrel.2021.10.010
  • Semple, (2010), Nat Biotechnol, 28, pp. 172, 10.1038/nbt.1602
  • Shahbazi, (2016), Nanomedicine, 11, pp. 1287, 10.2217/nnm-2016-0035
  • Sharifi, (2022), Adv Sci, 9, 10.1002/advs.202102678
  • Shi, (2014), Nat Genet, 46, pp. 482, 10.1038/ng.2941
  • Shi, (2019), Hum Gene Ther Clin Dev, 30, pp. 7, 10.1089/humc.2018.112
  • Shirley, (2014), pp. 93
  • Sicco, (2021), Sci Rep, 11, pp. 19942, 10.1038/s41598-021-98828-6
  • Simbulan-Rosenthal, (2019), Cancers (Basel), 11, 10.3390/cancers11101490
  • Simbulan-Rosenthal, (2019), J Oncol, 2019, 10.1155/2019/6486173
  • Simbulan-Rosenthal, (2022), Int J Mol Sci, 23, 10.3390/ijms23042333
  • Singh, (2001), Molecular therapy, 4, pp. 157, 10.1006/mthe.2001.0430
  • Singh, (2021), J Control Release, 338, pp. 394, 10.1016/j.jconrel.2021.08.054
  • Smith, (2021), Cancers (Basel), 13, 10.3390/cancers13215433
  • Soengas, (2003), Oncogene, 22, pp. 3138, 10.1038/sj.onc.1206454
  • Soldevilla, (2016), Oncotarget, 7, pp. 23182, 10.18632/oncotarget.8095
  • Sood, (2021), Integr Cancer Ther, 20, 10.1177/1534735421990078
  • Strobel, (2019), Biomedicines, 7, 10.3390/biomedicines7030069
  • Strojan, (2010), Radiol Oncol, 44, pp. 1, 10.2478/v10019-010-0008-x
  • Su, (2005), Oncogene, 24, pp. 7552, 10.1038/sj.onc.1208911
  • Sumimoto, (2006), J Exp Med, 203, pp. 1651, 10.1084/jem.20051848
  • Swaika, (2014), Drug Des Devel Ther, 8, pp. 775
  • Tamura, (2021), Neurosurgical review, 44, pp. 29, 10.1007/s10143-019-01203-3
  • Tang, (2021), Front Cell Dev Biol, 9
  • Tang, (2015), International journal of clinical and experimental medicine, 8, pp. 12644
  • Todd, (2009), Metallomics, 1, pp. 280, 10.1039/b907567d
  • Tomicic, (2002), Oncogene, 21, pp. 2141, 10.1038/sj.onc.1205280
  • Topalian, (2012), N Engl J Med, 366, pp. 2443, 10.1056/NEJMoa1200690
  • Tyrell, (2017), Melanoma Manag, 4, pp. 61, 10.2217/mmt-2016-0018
  • Un, (2011), Mol Pharm, 8, pp. 543, 10.1021/mp100369n
  • Uong, (2010), J Cell Physiol, 222, pp. 38, 10.1002/jcp.21935
  • Velasco, (2007), Molecular Neurobiology, 36, pp. 60, 10.1007/s12035-007-0002-5
  • Vile, (1993), Cancer research, 53, pp. 3860
  • Vinagre, (2013), Nat Commun, 4, pp. 2185, 10.1038/ncomms3185
  • Vredevoogd, (2019), Cell, 178, 10.1016/j.cell.2019.06.014
  • Wang, (2016), Int J Cancer, 138, pp. 918, 10.1002/ijc.29826
  • Wang, (2006), Semin Oncol, 33, pp. 513, 10.1053/j.seminoncol.2006.04.013
  • Wang, (2020), J Control Release, 322, pp. 95, 10.1016/j.jconrel.2020.03.023
  • Wei, (1998), Exp Cell Res, 241, pp. 66, 10.1006/excr.1998.4005
  • Wei, (2016), Med Oncol, 33, pp. 88, 10.1007/s12032-016-0804-2
  • Wilson, (2016), Cancer Treat Res, 167, pp. 209, 10.1007/978-3-319-22539-5_8
  • Wu, (2012), Cancer J, 18, pp. 160, 10.1097/PPO.0b013e31824d4465
  • Wu, (2017), Proc Natl Acad Sci, 114, pp. 1660, 10.1073/pnas.1614775114
  • Xiao, (2021), ACS Appl Mater Interfaces, 13, pp. 6109, 10.1021/acsami.0c23005
  • Xu, (2020), Cytotherapy, 22, pp. S35, 10.1016/j.jcyt.2020.03.027
  • Xu, (2016), Cancer Lett, 381, pp. 41, 10.1016/j.canlet.2016.07.024
  • Yadav, (2014), Mol Cancer Ther, 13, pp. 2253, 10.1158/1535-7163.MCT-14-0257
  • Yahya, (2021), Life Sci, 269, 10.1016/j.lfs.2021.119087
  • Yang, (2009), Hematol Oncol Clin North Am, 23, pp. 583, 10.1016/j.hoc.2009.03.006
  • Yang, (2021), Applied Acoustics, 179, 10.1016/j.apacoust.2021.108056
  • Yang, (2018), Chin J Cancer Res, 30, pp. 656, 10.21147/j.issn.1000-9604.2018.06.10
  • Yokoyama, (2011), Nature, 480, pp. 99, 10.1038/nature10630
  • Zeng, (2019), ACS Appl. Mater. Interfaces, 11, pp. 30661, 10.1021/acsami.9b13135
  • Zeng, (2018), Acta Pharmacol Sin, 39, pp. 261, 10.1038/aps.2017.166
  • Zhang, (2016), Biomaterials, 104, pp. 269, 10.1016/j.biomaterials.2016.07.015
  • Zhang, (2012), Mol Ther, 20, pp. 1298, 10.1038/mt.2012.79
  • Zhi, (2021), J Control Release, 335, pp. 158, 10.1016/j.jconrel.2021.05.009
  • Zhibing, (2020), Indian J Pharm Sci, 82, pp. 45
  • Zhou, (2016), Sci Adv, 2, 10.1126/sciadv.1600102
  • Zhou, (2016), J Control Release, 244, pp. 336, 10.1016/j.jconrel.2016.06.014
  • Zhou, (2020), Med Drug Discov, 6, 10.1016/j.medidd.2020.100023
  • Zhou, (2020), Biomark Res, 8, pp. 39, 10.1186/s40364-020-00223-2
  • Zhou, (2018), Acta Pharm Sin B, 8, pp. 165, 10.1016/j.apsb.2018.01.007
  • Zimmer, (2015), J Transl Med, 13, pp. 351, 10.1186/s12967-015-0716-5
  • Zocchi, (2021), J Clin Med, 10, 10.3390/jcm10163760